Anxo Pharmaceutical Co., Ltd. (6677.TWO)
- Previous Close
16.25 - Open
16.30 - Bid 15.75 x --
- Ask 16.05 x --
- Day's Range
15.75 - 16.35 - 52 Week Range
15.75 - 46.45 - Volume
81,466 - Avg. Volume
60,942 - Market Cap (intraday)
895.818M - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
-- - EPS (TTM)
-1.03 - Earnings Date --
- Forward Dividend & Yield 0.40 (2.46%)
- Ex-Dividend Date Aug 26, 2024
- 1y Target Est
--
Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally. The company offers prescription and over the counter drugs in various therapeutic areas, such as cardiovascular, metabolism, CNS, diabetic, respiratory, anti-infection, dermatology, nephrology, urology, orthopedics, etc. It also offers drugs for antidiabetic/dyslipidaemic agents, cardiovascular/circulatory system, nervous system, hepatology/gastroenterology, anti-infectives/anti-viruses, hemodialysis/urinary system, respiratory system/antihistamine, analgesics, and others; and injections. The company was founded in 2003 and is headquartered in Taipei, Taiwan.
www.anxo.com.tw--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 6677.TWO
View MorePerformance Overview: 6677.TWO
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6677.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6677.TWO
View MoreValuation Measures
Market Cap
906.98M
Enterprise Value
1.25B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.01
Price/Book (mrq)
0.89
Enterprise Value/Revenue
1.40
Enterprise Value/EBITDA
37.49
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.39%
Return on Assets (ttm)
-1.63%
Return on Equity (ttm)
-4.62%
Revenue (ttm)
895.32M
Net Income Avi to Common (ttm)
-57.21M
Diluted EPS (ttm)
-1.03
Balance Sheet and Cash Flow
Total Cash (mrq)
361.14M
Total Debt/Equity (mrq)
63.78%
Levered Free Cash Flow (ttm)
76.1M